Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Labs

Ternium

With the market facing myriad pressure points – predominantly stubbornly high inflation along with general anxieties about an incoming recession – the bright side is that investors have options regarding the best undervalued value stocks for June. Still, you don't want to just chase deflated entities just because they're down.

The 3 Most Undervalued Value Stocks to Buy in June 2023

Simulations Plus

Tencent Music Entertainment Group 

Epsilon Energy Ltd

Gulf Resources

NuScale Power Corp

While it's a general rule of thumb that you get what you pay for, in the market, you can sneak in some overlooked compelling discounts, which might be the case with the below best affordable stocks to invest in. With a price tag under $50, these enterprises facilitate approachability while also delivering on the quality or relevance components.

7 Stocks Under $50 to Buy (and Never Sell)

GE HealthCare Technologies Inc

Intuitive Surgical

Johnson & Johnson

CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.

Solid Earnings Fuel Potential Bull Market in Medical Devices

Shopify

SoFi Technologies

Now that it has sold its logistics business, Shopify once again has a strong profit margin. InMode makes increasingly popular medical devices that perform noninvasive and minimally invasive cosmetic procedures.

3 Exceptional Growth Stocks You Can Buy With $200 Right Now

Medical device maker InMode's aesthetic products have been in high demand. This has led to some terrific growth numbers for the business.

Is This the Best Healthcare Stock to Buy Right Now?

Teladoc

Teladoc has recently put the focus on the path to profitability. InMode has delivered gains in earnings over time.

More Likely to 5X First: Teladoc vs. InMode

Axsome Therapeutics

Investing in growth stocks can be far less risky if you make smaller, more frequent purchases of your favorite companies. Axsome Therapeutics is a commercial-stage drugmaker that recently launched a new treatment for depression, one of the most commonly diagnosed disabilities.

2 Magnificent Growth Stocks You Can Buy With $150 Right Now

InMode is a medical device maker gaining a share of the rapidly growing market for minimally invasive cosmetic procedures. Despite a tough period for making comparisons, InMode reported first-quarter sales that rose 23.5% year over year.

1 Soaring Growth Stock That's Still an Unbeatable Bargain

InMode is a leading provider of innovative, energy-based, and minimally invasive aesthetic and medical treatment solutions. The company has seen explosive growth on both the top line and bottom line with revenues and EBITDA growing at a 46% and 58% CAGR, respectively.

InMode: A Compelling Investment In The Fast-Growing Medical Aesthetics Market

The average of price targets set by Wall Street analysts indicates a potential upside of 46% in InMode (INMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think InMode (INMD) Could Surge 45.95%: Read This Before Placing a Bet

The medical aesthetics specialist notched solid revenue and profitability beats in its first quarter. There was a big catch to its performance, however.

Why InMode Stock Plummeted by 10% on Tuesday

InMode (INMD) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.40 per share a year ago.

InMode (INMD) Q1 Earnings and Revenues Top Estimates

InMode is a pioneer, first mover and leader in the field of minimally-invasive treatment and it generates mouth-watering returns. InMode is set to exceed investors' expectations embedded in today's share price even if a recession hits. Demand will likely prove far more resilient than the market is pricing in.

InMode: Undervalued Even Under Recessionary Conditions

InMode Ltd. (NASDAQ:INMD ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and CEO Shakil Lakhani - President, North America Yair Malca - Chief Financial Officer Spero Theodorou - Chief Medical Officer Conference Call Participants Michael Sarcone - Jefferies Danielle Antalffy - UBS Dane Reinhardt - Baird Mike Matson - Needham & Company Kyle Rose - Canaccord Genuity Operator Good day, and welcome to the InMode First Quarter 2023 Financial Results Conference Call.

InMode Ltd. (INMD) Q1 2023 Earnings Call Transcript

InMode beat first-quarter expectations Tuesday, but shares of the company tumbled on its lackluster sales and earnings outlook. The post InMode, A Top 1% Stock, Crumbles On Lackluster Sales, Earnings Outlook appeared first on Investor's Business Daily.

InMode, A Top 1% Stock, Crumbles On Lackluster Sales, Earnings Outlook

Unlimited profit potential and limited risk makes this option strategy attractive. The post This Option Strategy Makes INMD Stock More Attractive appeared first on Investor's Business Daily.

This Option Strategy Makes INMD Stock More Attractive

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a leader in its field, bringing in billions of dollars in annual earnings. Teladoc Health has steadily grown revenue, and telemedicine visits, by at least double-digit percentages.

3 Healthcare Stocks That Could Help Make You a Fortune

Amazon

Growth stocks can be unpredictable, but dollar-cost averaging is an easy way for everyday investors to avoid putting too many chips on a stock just before it tanks. Amazon and Shopify are two magnificent e-commerce stocks that are trading at bargain prices right now.

3 Exceptional Growth Stocks You Can Buy Now With $200 and Hold Forever

The consensus price target hints at a 33.7% upside potential for InMode (INMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe InMode (INMD) Could Rally 33.66%: Here's is How to Trade

InMode preannounced better-than-expected first-quarter sales and profits on Wednesday, pushing INMD stock closer to a breakout. The post InMode Soars On Bullish Pre-Announcement — But There's A Slight Caveat appeared first on Investor's Business Daily.

InMode Soars On Bullish Pre-Announcement — But There's A Slight Caveat

Shares of InMode Ltd. INMD climbed 1.1% in premarket trading Wednesday, after the Israel-based medical technologies company provided upbeat earnings guidance.

InMode stock gains after profit, revenue guidance tops expectations

YOKNEAM, Israel, April 12, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2023 before the Nasdaq market opens on Tuesday, May 2, 2023.

InMode Expects First Quarter 2023 Revenue Between $105.7-$105.9M, Non-GAAP Earnings per Diluted Share Between $0.50-$0.51

Etsy

Lululemon Athletica

Moderna

When the market is in the doldrums, it's time to go bargain hunting. Many top growth stocks have suffered in recent times -- and some have what it takes to soar when the general environment improves.

5 Top Growth Stocks to Buy Before the Next Bull Market

InMode is a small-cap medical device company that invented a new way to do plastic surgery in a non-invasive way, via radio waves. The company is dominating its niche market, and the stock is up almost 400% since the IPO.

News for Inmode Ltd Stock (INMD)